The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of carboplatin (C), pegylated liposomal doxorubicin (PLD) and everolimus (E) in platinum-sensitive epithelial ovarian, Fallopian tube or primary peritoneal cancer in first relapse (NCT01281514).
 
Lainie P. Martin
Consulting or Advisory Role - Immunogen
Research Funding - Abbvie (Inst); Clovis Oncology (Inst); Immunogen (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Sanofi (Inst); Tesaro (Inst); TetraLogic Pharmaceuticals (Inst); Teva (Inst)
Travel, Accommodations, Expenses - Immunogen
 
Angela Jain
Consulting or Advisory Role - Castle Biosciences
Travel, Accommodations, Expenses - Castle Biosciences
 
Christina Chu
No Relationships to Disclose
 
Gina Mantia-Smaldone
No Relationships to Disclose
 
Stephen C. Rubin
No Relationships to Disclose
 
Eric A. Ross
No Relationships to Disclose
 
Russell J. Schilder
Consulting or Advisory Role - Celsion; Clovis Oncology; Merrimack